Pozen Inc. (POZN) reported positive results from two Phase 3 clinical trials of PA32540, a coordinated-delivery tablet of immediate-release omeprazole and delayed release aspirin. The primary endpoint were met in both studies and the studies met their key secondary endpoints.
Pozen has gapped open sharply higher Thursday morning and is now up 0.80 at $5.60, with volume at nearly a 4-month high. The stock has surged to a 10-month high.
by RTT Staff Writer
For comments and feedback: email@example.com